Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07111117
Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma
Overview
The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.
Sponsor
Institut Curie
Phase
Phase 2
Contacts
Carole Cagnot
carole.cagnot@curie.fr
+33147111891
ClinicalTrials.gov
NCT07111117Drug / Compound
123I-MIBG
Isotope(s):
IODINE-123
Radioisotope: I-123
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 13.2 Hours
Decay Mode: BETA, GAMMA
Energy: Beta: 127 keV (14%), 154 keV (2%) Gamma: 539 keV (1%), 159 keV (83%), 27 keV (71%)
Range: N/A
Decay Daughters: Te123 (Stable)
Status: FDA Approvals: DATSCAN®(2011), ADREVIEW® (2008)
Target(s):
- NET
18F-MFBG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- NET
Share your feedback
Help us improve your experience